Physician profile
John J Chen
NPI 1437391083
$82,395.65
in general payments reported to CMS, 2019-2025
13 companies · $24K in 2025
The $24K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $550 · 2021: $10K · 2022: $19K · 2023: $8,868 · 2024: $20K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $29K · Travel and Lodging: $20K · Honoraria: $3,575 · Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $28,952.90 |
| Travel and Lodging | $19,694.37 |
| Honoraria | $3,575.00 |
| Food and Beverage | $614.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb Sa | $38,767.89 | 2021-2025 | Rystiggo |
| Horizon Therapeutics Plc | $20,447.15 | 2021-2023 | Uplizna |
| Ucb Gmbh | $15,652.62 | 2025 | |
| Genentech, INC. | $2,400.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $1,764.17 | 2021-2025 | Ultomiris, Strensiq |
| Dompe Farmaceutici S.P.A. | $1,266.40 | 2025 | |
| Merck Sharp & Dohme LLC | $1,000.00 | 2022-2023 | |
| Biogen, INC. | $549.85 | 2019 | |
| Alcon Vision LLC | $246.24 | 2021-2025 | Hydrus Microstent |
| Amgen INC. | $166.81 | 2024 | Uplizna |
| Tarsus Pharmaceuticals, INC. | $69.06 | 2025 | Xdemvy |
| Boston Scientific Corporation | $33.43 | 2025 | General - Vascular Access |
| Eisai INC. | $32.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.